All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-10-07T15:39:46.000Z

Phase III study of omidubicel in patients with high-risk hematologic malignancies meets all 3 secondary endpoints

Oct 7, 2020
Share:

Bookmark this article

On October 6, 2020, positive topline secondary endpoint data were released from the randomized, multicenter, phase III omidubicel study (NCT02730299) in 125 patients with high-risk hematological malignancies. In May, the AML Hub reported on the results regarding the primary endpoint of this international study, which showed that treatment with omidubicel significantly reduced the median time to neutrophil engraftment by 10 days compared to standard umbilical cord blood transplant (p < 0.001). It was generally well tolerated, with a higher percentage of patients achieving successful neutrophil engraftment.1,2

In the new announcement, all three secondary endpoints have shown a statistically significant improvement for patients treated with omidubicel compared to the comparator group.1 These secondary endpoints were:

  • The proportion of patients who achieved platelet engraftment by Day 42,
  • The proportion of patients with Grade 2/3 bacterial or invasive fungal infections in the first 100 days posttransplant, and
  • The number of days alive and out of hospital in the first 100 days posttransplant.

The full data sets are due to be presented at a medical meeting by the end of the year, as well as submitted to the U.S. Food and Drug Administration (FDA) for a biologics license. The positive primary and secondary endpoints of this study show omidubicel to be a promising treatment for patients who do not have a matched related donor of suitable age.         

  1. Gamida Cell. Gamida Cell announces positive topline data on secondary endpoints from phase 3 clinical study of omidubicel in patients with hematologic malignancies. https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cell-announces-positive-topline-data. Published Oct 6, 2020. Accessed Oct 7, 2020.
  2. Gamida Cell. Gamida Cell announces positive topline data from phase 3 clinical study of omidubicel in patients with high-risk hematologic malignancies. https://investors.gamida-cell.com/node/7236. Published May 12, 2020. Accessed Oct 7, 2020.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox